AMNEAL PHARMACEUTICALS, INC. (AMRX) Operating cash flow 2016–2025
AMNEAL PHARMACEUTICALS, INC. (AMRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$340.0MFY2025 · since FY2016: $115.1M → $340.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $340.0M | +15.2% |
| FY2024 | $295.1M | -14.6% |
| FY2023 | $345.6M | +430.8% |
| FY2022 | $65.1M | -73.1% |
| FY2021 | $241.8M | -36.2% |
| FY2020 | $379.0M | +22128.8% |
| FY2019 | $1.7M | -99.3% |
| FY2018 | $250.2M | +6.9% |
| FY2017 | $234.2M | +103.5% |
| FY2016 | $115.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Net marginAMRX Gross profitAMRX Gross marginAMRX Operating incomeAMRX Operating marginAMRX Free cash flowAMRX Capital expendituresAMRX Return on equityAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Total liabilitiesAMRX Shareholders’ equityAMRX overview →